Skip to main content
Clinical Trials/NCT00006208
NCT00006208UnknownPhase 3

A Randomized, Double-Blind, Equivalence Trial Comparing Emtricitabine to Stavudine Within a Triple Drug Combination Containing Didanosine Plus Efavirenz in Antiretroviral-Drug Naive HIV-1 Infected Patients

Triangle Pharmaceuticals111 sites in 2 countriesStarted: August 2000Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 3
Locations
111

Study Overview

Brief Summary

The purpose of this study is to compare the safety and effectiveness of emtricitabine and stavudine when given with didanosine plus efavirenz to HIV-infected patients.

Study Design

Study Type
Interventional
Primary Purpose
Treatment
Masking
Double

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Industry

Study Sites (111)

Loading locations...

Similar Trials